Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Galapagos NV
Galapagos NV
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery
The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
ISPE announces 2024 Facility of the Year Awards category winners
The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Drug Delivery
Galapagos and NovAliX enter integrated drug discovery collaboration
The agreement follows Galapagos’ renewed focus on its key therapeutic areas of oncology and immunology
Research & Development
Galapagos expands fibrosis portfolio
Fibrosis small molecule programme has been announced as the focus of a partnership between Galapagos and Evotec
Research & Development
Pharnext announces R&D agreement with Galapagos
The main goal of this agreement is to generate an additional pipeline of novel synergistic drug combinations in a broad set of indications
Research & Development
Galapagos ends inflammation partnership with Janssen
Long-running alliance started in 2007
Research & Development
AbbVie and Galapagos to co-develop cystic fibrosis therapies
Firms aim to start Phase 1 trials at end of 2014
Research & Development
Galapagos appoints CEO of Service Division
David Smith returns to the Belgian firm in new role
Research & Development
Galapagos receives €2.5m grant for IBD research
IWT-funded project aims to identify new compounds for future treatment of IBD
Subscribe now